Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 31, 2015 1:40 AM ET

Healthcare Equipment and Supplies

Company Overview of ZOLL Medical Corporation

Company Overview

ZOLL Medical Corporation develops, manufactures, and markets resuscitation devices, related data management and software solutions, and temperature management technology worldwide. The company provides technologies that help clinicians, EMS and fire professionals, and lay rescuers in treating victims needing resuscitation and critical care. It offers lifevest wearable defibrillators for various indications comprising heart attack, before or after bypass surgery, or stent placement; patients with cardiomyopathy or congestive heart failures; and patients awaiting an implantable defibrillator or after removal of an implantable device due to infection or other reasons, as well as AutoPulse, an a...

269 Mill Road

Chelmsford, MA 01824

United States

Founded in 1980

1,908 Employees





Key Executives for ZOLL Medical Corporation

Chief Executive Officer and Executive Director
Age: 57
President of ZOLL Data Management Products
Age: 51
President of ZOLL Core Products
Age: 51
President of Circulation
President of ZOLL LifeVest
Compensation as of Fiscal Year 2015.

ZOLL Medical Corporation Key Developments

Baku 2015 Equips European Games with ZOLL AED Plus to Treat Sudden Cardiac Arrest

ZOLL Medical Corporation announced that the Baku 2015 European Games, being held 12-28 June in Baku, Azerbaijan, will be equipped with the ZOLL AED Plus in the event that anyone attending or participating in this inaugural edition of the European Games experiences a sudden cardiac arrest. Eighty AED Plus units will be distributed among the mobile medical teams and be available across all Baku 2015 venues. According to the Operations Committee of the Baku Games, the AED Plus was recommended because of its CPR feedback technology. In addition to providing a shock if needed, the AED Plus features Real CPR Help technology, real-time audio and visual feedback to guide rescuers to the correct depth and rate of chest compression to deliver high-quality CPR and positively impact outcomes.

Opto Circuits Wins $23 Million in a Case Against Zoll

Opto Circuits (India) Ltd. has informed in a filing to BSE that its group company Cardiac Science Corporation has won a long-standing dispute over the company's wearable defibrillator technology. A 12-person jury in Los Angeles Superior Court has unanimously decided in favour of the company's breach of contract claims against Zoll Medical Corporation, and Zoll LifeCor Corporation, awarding Cardiac Science USD 22,991,985 in lost royalties. The dispute relates to the company's patented wearable defibrillator technology. In 2002, LifeCor began marketing its LifeVest product, which infringed a number of Cardiac Science's patents. To avoid infringement claims, LifeCor entered into a cross-license agreement with Cardiac Science and was able to continue selling its device.

ZOLL®Medical Corporation's ResQCPR System Receives Premarket Approval from FDA

ZOLL®Medical Corporation announced that the company’s ResQCPR System has been granted premarket approval (PMA) by the U.S. Food and Drug Administration (FDA) to market and begin U.S. distribution of the CPR adjunct system. The technology, which has been shown to improve the likelihood of survival in adult patients with non-traumatic cardiac arrest, is expected to be commercially available in mid-2015. A pivotal study evaluating the ResQCPR System, known as the ResQTRIAL, which the FDA considered in its approval process, demonstrated a 49% increase in survival to one year in adult patients who experienced out-of-hospital cardiac arrest of presumed cardiac etiology, as compared to treatment with conventional manual CPR. If widely implemented, the ResQCPR System could save thousands of lives each year in the U.S. from out-of-hospital cardiac arrest alone, based on these study results. The ResQCPR System uses Intrathoracic Pressure Regulation (IPR), a proprietary, non-invasive therapy developed by Advanced Circulatory Systems Inc. of Roseville, Minn., which ZOLL acquired in January 2015. This innovative technology uses the body’s own mechanisms to enhance circulation without the use of pharmaceutical or other agents. The ResQCPR System is comprised of the ResQPOD® Impedance Threshold Device and the ResQPUMP® Active Compression-Decompression CPR Device, which work synergistically to improve perfusion.

Similar Private Companies By Industry

Company Name Region
MedChem Products, Inc. United States
Optima Neuroscience, Inc. United States
FishVet, Inc. United States
Alma Lasers, Inc. United States
Euclid Systems Corp United States

Recent Private Companies Transactions

December 22, 2014
Advanced Circulatory Systems, Inc.
November 17, 2014
Post-Hypothermia Corporation
October 28, 2014
Impact Instrumentation Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOLL Medical Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at